(Reuters) -Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare and progressive genetic disease.
The approval expands the company’s presence in this market as it combats weak sales of its older cystic fibrosis drug Trikafta.
The new once-daily triple combination therapy, branded Alyftrek, was approved to treat patients aged 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that responds to the therapy.
Cystic fibrosis is an inherited disorder resulting from the absence of a specific protein, which disrupts salt and water movement in and out of cells in various organs.
(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)
Comments